1h Free Analyst Time
The idiopathic pulmonary fibrosis (IPF) market is forecasted to grow by USD 1.47 billion during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the idiopathic pulmonary fibrosis (IPF) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of respiratory diseases, growing geriatric population, and increase in number of smokers.
The idiopathic pulmonary fibrosis (IPF) market is segmented as below:
By Route Of Administration
- Oral
- Parenteral
By Drug Class
- Systemic corticosteroids
- Immunosuppressants
- Tyrosine kinase inhibitors
- Anti-fibrotic agents
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the idiopathic pulmonary fibrosis (IPF) market covers the following areas:
- Idiopathic pulmonary fibrosis (IPF) market sizing
- Idiopathic pulmonary fibrosis (IPF) market forecast
- Idiopathic pulmonary fibrosis (IPF) market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global idiopathic pulmonary fibrosis (IPF) market: Alembic Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics PLC, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in drug pipeline for IPF."
According to the report, one of the major drivers for this market is the increasing prevalence of respiratory diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alembic Pharmaceuticals Ltd.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celix Pharma Ltd.
- Cipla Inc.
- Daewoong Pharmaceutical Co. Ltd.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Galapagos NV
- Galecto Inc.
- GNI Group Ltd.
- Horizon Therapeutics Plc
- Intas Pharmaceuticals Ltd.
- Jubilant Pharmova Ltd.
- Liminal BioSciences Inc.
- MediciNova Inc.
- Merck and Co. Inc.
- Mission Therapeutics
- Novartis AG
- SHIONOGI Co. Ltd.
- United Therapeutics Corp.
